-
Comparing Risk of Bias Assessment Requirements Between the EU JCA and European HTA Agencies
Sep 9, 2025, 16:22 PM -
Exploring Evidence Gaps in National Institute for Health and Care Excellence Early Value Assessments
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective
Sep 9, 2025, 16:22 PM -
Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Lung Cancer Patients Using Machine Learning
Sep 9, 2025, 16:22 PM -
Global Pricing Meets Domestic Policy: Analyzing the Financial Impact of the Most-Favored Nation Approach on the United States Medicine Prices
Sep 9, 2025, 16:22 PM -
Evidence Strategy Starts Early: Integrating HTA Needs Through PICO Simulation in Metastatic Castration-Resistant Prostate Cancer
Sep 9, 2025, 16:22 PM -
Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions
Sep 9, 2025, 16:22 PM -
Estimating Healthcare Resource Use Associated With the Treatment of Phenylketonuria in the United States
Sep 9, 2025, 16:22 PM -
Evolving JCA Perspectives From EU Stakeholders and the Impact on Manufacturers
Sep 9, 2025, 16:22 PM -
Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies
Sep 9, 2025, 16:22 PM -
Beyond the Mean: Do Distribution-Based Metrics Offer Greater Insight Into Predictors of Societal Health Preferences? A Secondary Analysis of 42 EQ-5D-5L Value Sets
Sep 9, 2025, 16:22 PM -
Addressing the Impact of Alzheimer’s Disease on Care Capacity in the Netherlands: Implications for Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Disease Progression in Patients With Primary Hyperoxaluria: A Retrospective Cohort Study
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review
Sep 9, 2025, 16:22 PM -
A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan
Sep 9, 2025, 16:22 PM -
Nephrotoxicity of Antisense Oligonucleotide Therapies in Duchenne Muscular Dystrophy: A Warning or a Challenge?
Sep 9, 2025, 16:22 PM -
Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches
Sep 9, 2025, 16:22 PM -
The Economic Burden of Parkinson's Disease in the Netherlands: From Societal Impact to Investments in Health Solutions
Sep 9, 2025, 16:22 PM
